Epilepsy assets
We curate a list of over 200 assets in development for epilepsy and developmental and epileptic encephalopathies. The database includes developer and program names, modality, target indication, and development stage. This commercial product is available to support business development activities and competition analysis.
Most recent update August 2025. By modality: 133 small molecule programs, 35 gene therapies, 31 ASOs, 10 other. By stage: 22 Pivotal trials, 40 Phase 2, 27 Phase 1, 24 late preclinical.
For impatient patients
“#ImpatientRevolution is a free digital download eBook which is a must-read for charities about to embark on the journey towards drug development and clinical trials. Packed full of practical advice and tools, it’s a useful reference to guide you through the process.”
— Rare Revolution Magazine, Spring 2017
This eBook is a guide for impatient patient organizations – those wanting to accelerate the development of new medicines for their disease by taking an active role. It explains why and how companies develop drugs for rare diseases, and how patient organizations can use this knowledge to analyze their disease field, to identify the main gaps, and to design strategies to get pharmaceutical companies to develop new treatments for their disease.